Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality8/10

Cardinal Health lifts FY27 guidance on strong Q1, initiates growth catalysts

Nov 5, 2026, 6:57 AM EST1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Raised guidance, completed buyback, and CVS renewal plus planned AdaptHealth deal provide near-term catalysts and potential multiple expansion; offset by tariff-related risk being excluded from baseline growth.

AI summary

What happened, with direct paths to the underlying reporting

Cardinal Health reported Q1 FY27 revenue of $67.5 billion, +5% YoY, and raised its FY27 non-GAAP EPS guidance to $12.80–$13.00. The company completed a $500 million share repurchase, reaffirmed growth drivers, and disclosed a planned AdaptHealth Diabetes Health acquisition in Q3 FY27 alongside a Lilly-backed real-world evidence study (INSIGHT-IBD). These moves signal improved visibility and potential for multiple expansion amid a favorable pricing backdrop outside tariffs.

Q1 FY27 revenue $67.5B, up 5% YoY. GAAP EPS $2.38, up 27%.
Non-GAAP EPS $3.26, up 28% year over year.
FY27 non-GAAP EPS guidance raised to $12.80–$13.00 (+17–19% ex-tariff).
$500M accelerated share repurchase completed in Q1.
CVS renewal of distribution agreements; AdaptHealth Diabetes Health acquisition planned; Lilly INSIGHT-IBD study launched.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.